← All trials
NCT06592261
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2024
- Primary completion
- Aug 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Sep 19, 2024
- Last posted
- Nov 8, 2024
- Enrollment
- 15
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Columbia UniversityLead sponsor
- Columbia UniversityOfficial
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- Columbia UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.